Fox KM; EURopean trial On reduction of cardiac events with Perin- dopril in stable coronary Artery disease Investigators. Efficacy of per- indopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782 788. 127. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058 2068. 128. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S; Blood Pressure Lowering Treatment Tri- alists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of ran- domized trials. Arch Intern Med. 2005;165:1410 1419. 129. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin an- giotensin system on proteinuria in renal disease. Ann Intern Med. 2008; 148:30 48. 130. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiya- garajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study (ELITE II). Lancet. 2000;355:1582 1587. 131. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [pub- lished correction appears in Lancet. 2009;374:1744]. Lancet. 2003;362: 759 766. 132. 